These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 33079250

  • 61. Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT.
    Gomez E, Tran PT, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.
    Clin Nucl Med; 2019 Apr; 44(4):e313-e314. PubMed ID: 30789396
    [Abstract] [Full Text] [Related]

  • 62. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake.
    Werner RA, Bundschuh RA, Bundschuh L, Lapa C, Yin Y, Javadi MS, Buck AK, Higuchi T, Pienta KJ, Pomper MG, Lodge MA, Gorin MA, Rowe SP.
    Mol Imaging Biol; 2020 Feb; 22(1):190-197. PubMed ID: 31140110
    [Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 65. 18F-DCFPyL PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer: Prospective Trial with Pathologic Confirmation.
    Ulaner GA, Thomsen B, Bassett J, Torrey R, Cox C, Lin K, Patel T, Techasith T, Mauguen A, Rowe SP, Lindenberg L, Mena E, Choyke P, Yoshida J.
    Radiology; 2022 Nov; 305(2):419-428. PubMed ID: 35852431
    [Abstract] [Full Text] [Related]

  • 66. Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study.
    Meijer D, van Leeuwen PJ, Oosterholt PMJ, Bodar YJL, van der Poel HG, Hendrikse NH, Donswijk ML, Wondergem M, Vellekoop AE, van Moorselaar RJA, Nieuwenhuijzen JA, Oprea-Lager DE, Vis AN.
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2960-2969. PubMed ID: 33547552
    [Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69. Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions.
    Wondergem M, van der Zant FM, Broos WAM, Knol RJJ.
    J Nucl Med; 2021 Oct; 62(10):1422-1429. PubMed ID: 33547211
    [Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76. Patterns of disease detection using [18F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial.
    Koschel S, Taubman K, Sutherland T, Yap K, Chao M, Guerrieri M, Benson A, Starmans M, Byrne G, Ong G, Macleod C, Foo M, Wong LM, Gyomber D, Ng M.
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3712-3722. PubMed ID: 33852051
    [Abstract] [Full Text] [Related]

  • 77. Pattern of failure in prostate cancer previously treated with radical prostatectomy and post-operative radiotherapy: a secondary analysis of two prospective studies using novel molecular imaging techniques.
    Rowe LS, Harmon S, Horn A, Shankavaram U, Roy S, Ning H, Lindenberg L, Mena E, Citrin DE, Choyke P, Turkbey B.
    Radiat Oncol; 2021 Feb 10; 16(1):32. PubMed ID: 33568190
    [Abstract] [Full Text] [Related]

  • 78. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RA, Bailey DL, Budd R, Hicks RJ, Francis RJ, Lawrentschuk N.
    BJU Int; 2018 Nov 10; 122(5):783-793. PubMed ID: 29726071
    [Abstract] [Full Text] [Related]

  • 79. 18F-DCFPyL PET/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy.
    Wondergem M, van der Zant FM, Broos WAM, Roeleveld TA, Donker R, Ten Oever D, Geenen RWF, Knol RJJ.
    Eur J Nucl Med Mol Imaging; 2021 Feb 10; 48(2):521-531. PubMed ID: 32719916
    [Abstract] [Full Text] [Related]

  • 80. Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy.
    Sawicki LM, Kirchner J, Buddensieck C, Antke C, Ullrich T, Schimmöller L, Boos J, Schleich C, Schaarschmidt BM, Buchbender C, Heusch P, Rabenalt R, Albers P, Antoch G, Müller HW, Hautzel H.
    Eur J Nucl Med Mol Imaging; 2019 Jul 10; 46(7):1542-1550. PubMed ID: 30879122
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.